Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 19/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 19/20 | 0.53 |
| ▸ | PARP1 | P09874 | 13/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829611 | 0.84 | TNKS (0.72) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL17829629 | 0.83 | TNKS (0.56) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL17829732 | 0.80 | TNKS (0.71) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL29784025 | 0.79 | TNKS (0.71) | TNKSTNKS2PARP1PARP2CYP1A1 | |
| SCHEMBL4505299 | 0.79 | TNKS (0.71) | TNKSTNKS2PARP1PARP2CYP1A1 | |
| SCHEMBL17829759 | 0.77 | HPGD (0.54) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL17829713 | 0.75 | TNKS (0.67) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL17829731 | 0.74 | TNKS (0.54) | TNKSTNKS2PARP1PARP2CYP1A1 | |
| SCHEMBL17829723 | 0.73 | TNKS (0.70) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL27961710 | 0.70 | TNKS (0.55) | TNKSTNKS2PARP1PARP2CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | TNKS 1771/4885TNKS2 2811/4885PARP1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.